HCPLive Editorial Staff

Recently, Jennifer B. Green, MD, Duke Health, led a 4 person panel of Duke doctors on emerging topics in diabetes management.

The June 22 symposium, called Institutional Perspectives in Type 2 Diabetes: Contemporary Approaches to Insulin Treatment, was part of HCPLive's State of the Science program.

Green kicked the program off with a discussion on the role of insulin therapy in contemporary diabetes management. That was followed by a talk about insulin initiation by Andrea D Coviello, MD, Duke Health,

Next, Susan E. Spratt, MD, Duke Health, talked about intensification and modification of insulin therapy. The final segment was about integrating technology into insulin management, led by Hiba Abou Assi, MD, Duke Health.


Videos

Dr. Jennifer Green led a panel in discussing new treatments and topics in diabetes care.

Institutional Perspectives in Type 2 Diabetes: Contemporary Approaches to Insulin Treatment

A group of experts from the University of North Carolina at Chapel Hill have come together to discuss many crucial topics for the treatment of patients with 

 State of the Science Summit called Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease.

Leading the group was Millie Long, MD, MPH. Joining Long was Kimberly Weaver, MD, Edward Barnes, MD, MPH, and Hans Herfarth, MD, PhD.

The program began with Weaver’s discussion on managing IBD during COVID-19. Weaver’s discussion was followed by Barnes talking about the early use of biologics and Herfarth’s explainer on newly approved and emerging therapies in IBD.

Long closed out the event with a talk about taking a treat to target approach in IBD.

A group of experts discuss new and emerging therapies for IBD.

Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease

It is an exciting time for researchers looking at new treatments for 

Building on the success of the unapproved fecal microbiota transplantation (FMT) treatment for C difficile infections, several live microbiota therapeutics are currently in development.

State of the Science Summit, entitled Institutional Perspectives in Infectious Diseases: Management of C. Difficile, a group of experts discussed different topics involved in the care of CDI. 

The summit was chaired by Jason Sniffen, DO, FACP, FIDSA, of Advent Health.

Joining Sniffen was Mathieu Millette, PhD, Bio-K+, Kerry Group, Maryam Kashi, DO, Advent Health System, and Stuart Johnson, MD, Veterans Affairs.

The event kicked off with Millette’s discussion on understanding C difficile infections. Following Millette was Sniffen’s discussion on standard of care and Kashi’s talk about emerging treatment options.

Concluding the evening was Johnson’s explainer on clinical trials for C difficile infections.

There are several emerging treatments for C difficile infections.

State of the Science: Managing C Difficile Infections

 is a crucial topic in psychiatry, with new potential treatments emerging that could overcome the barriers of resistance that impact many patients treated with antipsychotics.

Recently, Geoffrey Grammer, MD, Greenbrook TMS NeuroHealth Centers, led a panel discussing some of these treatments, including esketamine, and how psychiatrists can improve care for this patient population.

The panel, which was called Institutional Perspectives in Psychiatry: Addressing Challenges in Depression Treatment, is part of 

 State of the Science webinar program where experts discuss some key questions and initiatives in medicine.

Joining Grammer during the March 23 panel were Misty Borst, MD and William Sauvé, MD, both of Greenbrook TMS NeuroHealth Centers.

After introductions, Borst kicked off the webinar with a discussion on the overall burden of the disease. Following Borst was Sauvé’s talk on some newer treatment options, including esketamine.

With some question and answer periods sprinkled in, Sauvé and Grammer closed out the program with talks on integrating patient care and other treatment options.

There is a need for new medications for depression to overcome high rates of treatment resistance. 

HCPLive Editorial Staff

Articles